FAST NEWS: Simcere’s Covid drug trial shows promising results
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that newly published results of a Phase 2/3 clinical study for its innovative drug, Xiannuoxin, for the treatment of adult patients…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
